Summary
Hydrocodone bitartrate (HB) and acetaminophen (APAP) combination products are known to be abused via oral, intranasal, and intravenous self-administration. Benzhydrocodone HCl (KP201) is a prodrug of hydrocodone with limited bioavailability when taken intranasally or intravenously, or taken orally at supratherapeutic doses. This study assessed the abuse liability, relative bioavailability, and safety of KP201/APAP, compared with that of HB/APAP (Norco®), when administered at supratherapeutic oral doses to non-dependent, recreational opioid users. Both KP201/APAP and HB/APAP were generally well tolerated and had similar Drug Liking scores, but KP201/APAP displayed lower peak and cumulative systemic exposure to hydrocodone at high and mid oral doses.
Register to download
Oral Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone
You may also be interested in:
Poster
Predicting Screen Failure Rates of Human Abuse Potential Studies
Human Abuse Potential (HAP) studies are required for New Drug Approvals of all drugs that have a potential psychoactive effect. The steps of…
Capability
Pain Studies at PRA Early Development Services
PRA Health Sciences offers a range of pain models to assess pain perception and the efficacy of experimental analgesics in healthy volunteers and…
Case Study
PRA Teamwork Demonstrates Vision
A large pharmaceutical client selected PRA to conduct 2 Phase III epilepsy studies in India, Eastern and Western Europe, and Australia. PRA’s project…